認定特定非営利活動法人

1. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K; North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009 Mar 20;27(9):1394-400. Epub 2009 Feb 17.

2. Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009 Jul 1;15(13):4493-8. Epub 2009 Jun 16.

3. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S, Uematsu K, Nagai Y, Moriyama G, Miyazawa H, Ikebuchi K, Morita S, Kobayashi K, Hagiwara K. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2010 Feb 1;126(3):651-5.

4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8.

5. Ebara T, Kawamura H, Kaminuma T, Okamoto M, Yoshida D, Okubo Y, Takahashi T, Sakaguchi H, Kobayashi K, Yoshitaka A, Nakano T. Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma. J of Radiation Research 2012, vol./is. 53/2(288-94).

6. Satoh H, Inoue A, Kobayashi K, Maemondo M, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T. Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol. 2011 Aug;6(8):1413-7.

7. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T. Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial. The Onlogist. 2012;17(6):863-70.

8. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H; for the North-East Japan Study Group and the ALK Lung Cancer Study Group. A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer. Clin Cancer Res. 2012 Oct 15;18(20):5682-5689. Epub 2012 Aug 20.

9. Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemmah A. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012 Sep;7(9):1417-22.

10. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T;North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. 2013 Jan:24(1):54-9.

11. Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, Yamamoto N. Interstitial Lung Disease Associated With Gefitinib in Japanese Patients With EGFR-mutated Non-Small-Cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405) Jpn J Clin Oncol. 2013 Jun;43(6):664-8.

12. Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014 Feb;9(2):189-94.

13. Kawano Y, Okamoto I, Fukuda H, Ohe Y, Nakamura S, Nakagawa K, Hotta K, Kiura K, Takiguchi Y, Saka H, Okamoto H, Takayama K, Semba H, Kobayashi K, Kenmotsu H, Tsuboi M, Yamamoto N, Nukiwa T, Nakanishi Y. Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respir Investig. 2014 Nov;52(6):339-47.

14. Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung Cancer. 2014 Nov;86(2):195-200.

15. Morikawa N, Minegishi Y, Inoue A, Maemondo M, Kobayashi K, Sugawara S, Harada M, Hagiwara K, Okinaga S, Oizumi S, Nukiwa T, Gemma A; North-East Japan Study Group. First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. Expert Opin Pharmacother. 2015 Mar;16(4):465-72.

16. Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer. 2015 May;88(2):181-6.

17. Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T; North East Japan Study Group and Tokyo Cooperative Oncology Group. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann Oncol. 2015 May;26(5):888-94.

18. Satoshi Watanabe, Akira Inoue, Toshihiro Nukiwa, Kunihiko Kobayashi Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion Anticancer Res. 2015 Dec;35(12):6957-61.

19. Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T; North-East Japan Study Group. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Jpn J Clin Oncol. 2015 Jul;45(7):670-6.

20. Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K; North East Japan Study Group. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung Cancer. 2016 Sep;99:131-6.

21. Miura S, Maemondo M, Iwashima A, Harada T, Sugawara S, Kobayashi K, Inoue A, Nakagawa T, Takiguchi Y, Watanabe H, Ishida T, Terada M, Kagamu H, Gemma A, Yoshizawa H. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016). Invest New Drugs. 2017 Feb 1 Apr;35(2):227-234.

22. Inoue Y, Shiihara J, Miyazawa H, Ohta H, Higo M, Nagai Y, Kobayashi K, Saijo Y, Tsuchida M, Nakayama M, Hagiwara K. A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer. PLoS One. 2017 Apr 27;12(4):e0176525.

23. Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T. Updated Survival Outcomes of NEJ005/TCOG0902: A Randomised Phase II Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-Small Cell Lung Cancer With Sensitive EGFR Mutations. ESMO Open. 2018 Feb 23;3(2):e000313.

24. Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients With Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients From NEJ023 Study. Oncologist. 2018 Oct;23(10):1210-1217.

25. Satoshi Watanabe, O U Yamaguchi, A I Masumoto, Yuri Maeno, Yosuke Kawashima, Osamu Ishimoto, Shunichi Sugawara, Hirohisa Yoshizawa, Toshiaki Kikuchi, Toshihiro Nukiwa, Kunihiko Kobayashi Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs ANTICANCER RESEARCH 38: 4699-4704 (2018)

26. Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib Plus Bevacizumab Versus Erlotinib Alone in Patients With EGFR-positive Advanced Non-Squamous Non-Small-Cell Lung Cancer (NEJ026): Interim Analysis of an Open-Label, Randomised, Multicentre, Phase 3 Trial. Lancet Oncol. 2019 May;20(5):625-635.

27. Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020 Jan 10;38(2):115-123.

28. Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyabayashi T, Sakashita H, Matsumoto Y, Tanigawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Clinical Outcomes of Second-Line Chemotherapy in Patients With Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients From the NEJ023 Study. Oncologist. 2020 Apr;25(4):e668-e674. doi: 10.1634/theoncologist.2019-0593. Epub 2019 Nov 26.

29. Rintaro Noro , Kunihiko Kobayashi , Jiro Usuki , Makiko Yomota, Masaru Nishitsuji, Tsuneo Shimokawa, Masahiro Ando, Mitsunori Hino, Koichi Hagiwara, Akihiko Miyanaga, Masahiro Seike, Kaoru Kubota, Akihiko Gemma :; North East Japan Study group. Bevacizumab Plus Chemotherapy in Nonsquamous Non-Small Cell Lung Cancer Patients With Malignant Pleural Effusion Uncontrolled by Tube Drainage or Pleurodesis: A Phase II Study North East Japan Study Group Trial NEJ013B. Thorac Cancer. 2020 Jul;11(7):1876-1884.

30. Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Prof Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Prof Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Prof Koichi Hagiwara, Prof Toshihiro Nukiwa, Prof Satoshi Morita, Prof Kunihiko Kobayashi, Prof Makoto Maemondo. Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study. eBioMedicine. 2020 Jul 3;57:102861. doi: 10.1016/j.ebiom.2020.102861. Online ahead of print.

31. Kyoichi Kaira , Atsuto Mouri , Shingo Kato , Kenichi Yoshimura , Hiroshi Kagamu , Kunihiko Kobayashi A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non small cell lung cancer
    patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress) BMC Cancer . 2020 Oct 6;20(1):961. doi: 10.1186/s12885 020 07406 y.

32. Hajime Asahina , Kentaro Tanaka , Satoshi Morita , Makoto Maemondo , Masahiro Seike , Isamu Okamoto , Satoshi Oizumi , Hiroshi Kagamu , Kazuhisa Takahashi , Toshiak i Kikuchi , Takeshi Isobe , Kenji Sugio , Kunihiko Kobayashi A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients W ith EGFR Mutated Advanced Non Small cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801) Clin Lung Cancer . 2021 Mar;22(2):147 151. doi: 10.1016/j.cllc.2020.09.023. Epub 2020 Oct 16.

33. Yukari Tsubata , Shun Shinomiya , Koji Inoue , Nobuhisa Ishikawa , Ryota Saito , Kazuhisa Nakashima , Katsuyuki Hotta , Akinobu Hamada , Fumio Nagashima , Yuichi Ando , Satoshi Morita , Kunihiko Kobayashi , Takeshi Isobe Protocol for a multi site, cluster randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non small cell lung cancer: the ENSUR E GA study BMC Geriatr . 2021 Jan 22;21(1):74. doi: 10.1186/s12877 021 02028 w.

34. Yuji Minegishi , Ou Yamaguchi , Shunichi Sugawara , Sho ichi Kuyama , Satoshi Watanabe , Kazuhiro Usui , Masahide Mori , Osamu Hataji , Toshihiro Nukiwa , Satoshi Morita , Kunihiko Kobayashi , Akihiko Gemma A phase II study of first line afatinib for patients aged ≥75 years with EGFR mutation positive advanced non small cell lung cancer: North East Japan Study Group trial NEJ027 BMC Cancer . 2021 Mar 1;21(1):208. doi: 10.1186/s12885 021 07861 1.

35. Kentaro Tanaka , Hajime Asahina , Junji Kishimoto , Yoshihiro Miyata , Takahiro Uchida , Kana Watanabe , Kosuke Hamai , Taishi Harada , Yukari Tsubata , Shunichi Sugawara , Kunihiko Kobayashi , Kenji Sugio , Satoshi Oizumi , Isamu Okamo to Osimertinib versus osimertinib plus chemotherapy for non small cell lung cancer with EGFR (T790M) associated resistance to initial EGFR inhibitor treatment: An open label, randomised phase 2 clinical trial Eur J Cancer . 2021 May;149:14 22. doi: 10.1016/j.ejca.2021.02.019. Epub 2021 Apr 1.

36. Yosuke Kawashima , Tatsuro Fukuhara , Haruhiro Saito , Naoki Furuya , Kana Watanabe , Shunichi Sugawara ,Shunichiro Iwasawa , Yoshio Tsunezuka , Ou Yamaguchi , Morihito Okada , Kozo Yoshimori , Ichiro Nakachi , Masahiro Seike , Koichi Azuma , Futoshi Kurimoto , Yukari Tsubata , Yuka Fujita , Hiromi Nagashima , Gyo Asai , Satoshi Watanabe , Masaki Miyazaki , Koichi Hagiwara , Toshihiro Nukiwa , Satoshi Morita , Kunihiko Kobayashi , Makoto Maemondo Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR mutant non small cell lung cancer (NEJ026): overall survival analysis of an open label, randomised, multicentre, phase 3 trial Lancet Respir Med . 2022 Jan;10(1):72 82. doi: 10.1016/S2213 2600(21)00166 1. Epub 2021 Aug 26.

37. Yukari Tsubata , Kana Watanabe , Ryota Saito , Atsushi Nakamura , Hiroshige Yoshioka , Mami Morita , Ryoichi Honda , Nobuhiro Kanaji , Satoshi Ohizumi , Daisuke Jingu , Taku Nakagawa , Kensuke Nakazawa , Atsuto Mouri ,Susumu Takeuch i , Naoki Furuya , Yuki Akazawa , Kiyotaka Miura , Eiki Ichihara , Makoto Maemondo , Satoshi Morita ,Kunihiko Kobayashi , Takeshi Isobe Osimertinib in poor performance status patients with T790M positive advanced non small cell lung cancer after progression of first and second generation EGFR TKI treatments (NEJ032B) Int J Clin Oncol . 2022 Jan;27(1):112 120. doi: 10.1007/s10147 021 02043 2. Epub 2021 Oct 13.

38. Tomoyasu Mimori, Takehito Shukuya, Ryo Ko, Yusuke Okuma, Tomonobu Koizumi, Hisao Imai, Yuichi Takiguchi, Eisaku Miyauchi, Hiroshi Kagamu, Tomohide Sugiyama, Keisuke Azuma, Yukiko Namba, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Kunihiko Kobayashi, Kazuhisa Takahashi Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study Cancers (Basel). 2022 Jan 11;14(2):331. doi: 10.3390/cancers14020331.

39. Satoshi Oizumi, Kei Takamura, Toshiyuki Harada, Motoko Tachihara, Naoto Morikawa, Ryoichi Honda, Satoshi Watanabe, Tetsuhiko Asao, Mamoru Kunisaki, Tatsuro Fukuhara, Rintaro Noro, Eiki Kikuchi, Yasuhiro Tsutani, Toshiyuki Tenma, Kunihiko Kobayashi, Hirotoshi Dosaka-Akita, North East Japan Study Group, Hokkaido Lung Cancer Clinical Study Group Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024 Int J Clin Oncol. 2022 Apr;27(4):676-683. doi: 10.1007/s10147-021-02113-5. Epub 2022 Jan 29.

40. Yukari Tsubata, Takamasa Hotta, Kosuke Hamai, Naoki Furuya, Toshihide Yokoyama, Ryota Saito, Atsushi Nakamura, Takeshi Masuda, Megumi Hamaguchi, Shoichi Kuyama, Ryoichi Honda, Tadashi Senoo, Masamoto Nakanishi, Masahiro Yamasaki, Nobuhisa Ishikawa, Kazunori Fujitaka, Tetsuya Kubota, Kunihiko Kobayashi and Takeshi Isobe A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study J Hematol Oncol. 2022 Apr 4;15(1):40. doi: 10.1186/s13045-022-01259-7.

41. Yukari Tsubata, Takamasa Hotta, Kosuke Hamai, Naoki Furuya, Toshihide Yokoyama, Ryota Saito, Atsushi Nakamura, Takeshi Masuda, Megumi Hamaguchi, Shoichi Kuyama, Ryoichi Honda, Tadashi Senoo, Masamoto Nakanishi, Masahiro Yamasaki, Nobuhisa Ishikawa, Kazunori Fujitaka, Tetsuya Kubota, Hiroshi Ohtsu, Kunihiko Kobayashi, Takeshi Isobe Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study) Ther Adv Med Oncol. 2022 Jul 21;14:17588359221110171. doi: 10.1177/17588359221110171. eCollection 2022.

42. Yuji Minegishi, Tomoe Akagami, Makoto Arai, Ryota Saito, Daisuke Arai, Kyoko Murase, Keita Miura, Satoshi Watanabe, Hiroyuki Sakashita, Takao Miyabayashi, Ryoichi Honda, Daisuke Jingu, Takamasa Hotta, Kazutoshi Isobe, Kensuke Nakazawa, Kenichiro Ito, Kei Takamura, Minehiko Inomata, Toshiyuki Harada, Rie Sakakibara, Taku Nakagawa, Hideki Shibuya, Kiyoshi Takenaka, Kunihiko Kobayashi, Masahiro Seike Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042) Lung Cancer. 2022 Oct;172:1-8. doi: 10.1016/j.lungcan.2022.07.009. Epub 2022 Jul 26.

43. Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura, Yukio Hosomi, Kana Watanabe, Satoshi Ikeda, Masahiro Seike, Yuka Fujita, Koichi Minato, Ryo Ko, Toshiyuki Harada, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue, for the North-East Japan Study Group Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR J Clin Oncol. 2022 Aug 12;JCO2102911. doi: 10.1200/JCO.21.02911. Online ahead of print.

44. Kensho Ohata, Takuya Gonokami, Shunpei Kinjo, Sadao Kato, Satoshi Morita, Kunihiko Kobayashi Structure of spirituality among high-school students differs depending on relationship with someone or something Greater (RSG) Current Psychology. 2022 Sep 28. doi: 10.1007/s12144-022-03694-8

45. Tetsuhiko Asao, Satoshi Watanabe, Takahiro Tanaka, Satoshi Morita and Kunihiko Kobayashi A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol BMC Cancer. 2022 Nov 4;22(1):1135. doi: 10.1186/s12885-022-10222-1.

46. Yukari Tsubata, Keita Kawakado, Kosuke Hamai, Naoki Furuya, Toshihide Yokoyama, Ryota Saito, Atsushi Nakamura, Takeshi Masuda, Megumi Hamaguchi, Shoichi Kuyama, Ryoichi Honda, Tadashi Senoo, Masamoto Nakanishi, Takamasa Hotta, Masahiro Yamasaki, Nobuhisa Ishikawa, Kazunori Fujitaka, Tetsuya Kubota, Kunihiko Kobayashi & Takeshi Isobe Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data Int J Clin Oncol. 2023 Jan;28(1):69-78. doi: 10.1007/s10147-022-02257-y. Epub 2022 Nov 10.

47. Ryo Okuda, Takashi Ogura, Shu Hisata, Tomohisa Baba, Yasuhiro Kondoh, Takafumi Suda, Takeshi Johkoh, Tae Iwasawa, Hiromi Tomioka, Masashi Bando, Arata Azuma, Yoshikazu Inoue, Toru Arai, Yutaro Nakamura, Atsushi Miyamoto, Yasunari Miyazaki, Hirofumi Chiba, Haruyuki Ishii, Naoki Hamada, Yasuhiro Terasaki, Ichiro Kuwahira, Shinji Sato, Shingo Kato, Takuji Suzuki, Susumu Sakamoto, Yasuhiko Nishioka, Noboru Hattori, Naozumi Hashimoto, Satoshi Morita, Nao Ichihara, Hiroaki Miyata, Koichi Hagiwara, Toshihiro Nukiwa, Kunihiko Kobayashi Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry Respir Investig. 2023 Jan;61(1):95-102. doi: 10.1016/j.resinv.2022.08.009. Epub 2022 Nov 15.

48. Atsushi Nakamura, Ou Yamaguchi, Keita Mori, Keita Miura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira Multicenter real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with PD-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study) Eur J Cancer. 2023 May;184:62-72. doi: 10.1016/j.ejca.2023.01.025. Epub 2023 Feb 11.

49. Akihiko Miyanaga, Hajime Asahina, Satoshi Watanabe, Takehito Shukuya, Yukari Tsubata, Yukio Hosomi, Shunichi Sugawara, Makoto Maemondo, Tetsuya Okano, Satoshi Morita, Kotone Matsuyama, Kunihiko Kobayashi, Masahiro Seike A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS) Clin Lung Cancer. 2023 Jun;24(4):371-375. doi: 10.1016/j.cllc.2023.01.008. Epub 2023 Feb 1.

50. Ryota Saito, Shunichi Sugawara, Ryo Ko, Koichi Azuma, Ryo Morita, Makoto Maemondo, Satoshi Oizumi, Kazuhisa Takahashi, Hiroshi Kagamu, Yukari Tsubata, Masahiro Seike, Toshiaki Kikuchi, Isamu Okamoto, Morita Satoshi, Hajime Asahina, Kentaro Tanaka, Kenji Sugio, Kunihiko Kobayashi Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study Eur J Cancer. 2023 May;185:83-93. doi: 10.1016/j.ejca.2023.02.023. Epub 2023 Mar 2.

51. Kazutaka Fujita, Ryo Arai, Satoshi Shoji, Ryota Saito, Motoko Nomura, Takamasa Hotta, Hajime Asahina, Masanori Kawakami, Ichiro Nakachi, Yukihiro Hasegawa, Kohei Okafuji, Aya Suzuki, Akihiko Miyanaga, Noriaki Sunaga, Hiromi Nagashima, Naoya Ikeda, Satoshi Watanabe, Yoshiaki Nagai, Megumi Furuta, Hidenori Kage, Daisuke Arai, Tatsuro Fukuhara, Masayuki Nakayama, Satoshi Morita, Kunihiko Kobayashi, Koichi Hagiwara Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine a trial Cancer Sci. 2023 May 3. doi: 10.1111/cas.15831. Online ahead of print.

52. Yuichi Sakairi, Ichiro Yoshino, Takekazu Iwata, Shigetoshi Yoshida, Kazuyoshi Kuwano, Arata Azuma, Shuji Sakai, Kunihiko Kobayashi; on behalf of the North East Japan Study Group A randomized controlled phase III trial protocol: perioperative pirfenidone therapy in patients with non-small-cell lung cancer combined with idiopathic pulmonary fibrosis to confirm the preventative effect against postoperative acute exacerbation: the PIII-PEOPLE study (NEJ034) J Thorac Dis. 2023 Mar 31;15(3):1486-1493. doi: 10.21037/jtd-22-535. Epub 2023 Mar 6.

1. Yoshihito Kogure, Shunichiro Iwasawa, Hideo Saka, Yoichiro Hamamoto, Akiko Kada, Hiroya Hashimoto, Shinji Atagi, Yuichi Takiguchi, Noriyuki Ebi, Akira Inoue, Takayasu Kurata, Isamu Okamoto, Masafumi Yamaguchi, Toshiyuki Harada, Masahiro Seike, Masahiko Ando, Akiko M Saito, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Nobuyuki Yamamoto, Akihiko Gemma Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. Lancet Healthy Longev. 2021 Dec;2(12):e791-e800. doi: 10.1016/S2666-7568(21)00255-5.

• 今、注目される呼吸器疾患治療薬　第1回：激変する肺がん治療：ドライバー変異の発見が3方向の治療戦略を展開

  (出典：医薬品医療機器レギュラトリーサイエンス　Vo.48, No.12 p.802～808 (2017))

• 今、注目される呼吸器疾患治療薬　第2回：創薬志向が高まる肺線維症：その臨床開発経過と今後の展望

  (出典：医薬品医療機器レギュラトリーサイエンス　Vo.49, No.2 p.98～104 (2018))

• 今、注目される呼吸器疾患治療薬　第3回：治療期間短縮が求められる結核治療：宿主側肉芽腫制御は創薬対象になりうるか？

  (出典：医薬品医療機器レギュラトリーサイエンス　Vo.49, No.4 p.200～206 (2018))

※無断転載・複製を禁ず

• 文部科学大臣賞 (萩原 弘一、長井 良昭、小林 国彦、宮澤 仁志、田中 知明)
• 日本肺癌学会 篠井・河合賞 (井上 彰)
• 日本呼吸器学会 奨励賞 (井上 彰)
• 東北医学会 奨学賞A (井上 彰)
• International Research Promotion Council (IRPC) World Scientists Forum International Award (小林 国彦)
• 日本学術振興会賞 (井上 彰)
• 後藤喜代子・ポールブルダリ科学賞（前門戸 任）
• Annals of Oncology 賞（井上 彰）